vTv Therapeutics LLC, a subsidiary of vTv Therapeutics Inc., has entered into a Second Amendment to its License Agreement with Newsoara Biopharma Co., Ltd. This new agreement expands Newsoara’s rights to the Company’s PDE4 inhibitor, HPP737, to include all countries globally, contingent on a $20 million upfront payment. The amended terms also include up to $50 million in development milestone payments, $65 million in sales-related milestone payments, and royalties in the mid single digits based on sales volumes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641489-26-000002), on February 02, 2026, and is solely responsible for the information contained therein.